Case Report: Neonatal type 3 mesenteric cystic lymphangioma with spontaneous hemorrhage managed by sclerotherapy
Background Mesenteric cystic lymphangiomas (MCLs) remain a clinical challenge when lesions are located in the mesentery with extension to the retroperitoneum. Although surgical resection represents the mainstream approach, complete excision of type 3 or type 4 MCL may be difficult or even impossible in certain patients. Therefore, sclerotherapy offers a feasible therapeutic option for these cases. Case presentation This report describes a neonate with type 3 MCL who underwent ultrasound-guided catheter drainage and intralesional sclerotherapy, achieving an excellent outcome and avoiding invasive surgical injury. A 1-day-old female neonate presented with abdominal distension and vomiting after initial feeding and was diagnosed with type 3 MCL by abdominal computed tomography. At postnatal ages 2 and 23 days, ultrasound-guided catheter drainage of the MCL was performed, with intracystic injection of bleomycin (concentration: 1 mg/mL, 0.5 mg/kg), respectively. The MCL regressed completely 1 year after sclerotherapy, and the patient was followed up for 3 years without recurrence. Conclusions Complete surgical resection of type 3 MCL may be difficult or even impossible and often causes severe trauma and complications. However, ultrasound-guided catheter drainage and bleomycin sclerotherapy as a minimally invasive approach is preferred because of its minimal invasiveness, repeatability, and reliable efficacy.
Authors
- Donglai Hu
- Junjie Chen
- Baoyuan Jin
- Zhijian Zhou
- Shanshan Wang
- Xuan Fang
- Xiaodong Guo
Institutions
- Wenzhou Medical University (CN)
- Jingzhou Maternal and Child Health Hospital (CN)
- Jinhua Academy of Agricultural Sciences (CN)
- Jinhua Central Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Surgery
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fsurg.2026.1985373
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jinhua Science and Technology Bureau